IE871210L - Tissue plasminogen activator - Google Patents

Tissue plasminogen activator

Info

Publication number
IE871210L
IE871210L IE871210A IE121087A IE871210L IE 871210 L IE871210 L IE 871210L IE 871210 A IE871210 A IE 871210A IE 121087 A IE121087 A IE 121087A IE 871210 L IE871210 L IE 871210L
Authority
IE
Ireland
Prior art keywords
tissue
plasminogen activator
tissue plasminogen
medicament
damage
Prior art date
Application number
IE871210A
Other versions
IE59895B1 (en
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/862,057 external-priority patent/US4976959A/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of IE871210L publication Critical patent/IE871210L/en
Publication of IE59895B1 publication Critical patent/IE59895B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Tissue plasminogen activator (t-PA), optionally together with superoxide dismutase (SOD), is used to manufacture a medicament for use in the inhibition of damage to jeopardised tissue during blood reperfusion. The medicament is for preventing damage to tissue following ischaemic attack, e.g. in myocardial tissue, when blood supply is restored.
IE121087A 1986-05-12 1987-05-11 Medicaments containing tissue plasminogen activator IE59895B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86204686A 1986-05-12 1986-05-12
US06/862,057 US4976959A (en) 1986-05-12 1986-05-12 T-PA and SOD in limiting tissue damage

Publications (2)

Publication Number Publication Date
IE871210L true IE871210L (en) 1987-11-12
IE59895B1 IE59895B1 (en) 1994-04-20

Family

ID=27127662

Family Applications (1)

Application Number Title Priority Date Filing Date
IE121087A IE59895B1 (en) 1986-05-12 1987-05-11 Medicaments containing tissue plasminogen activator

Country Status (13)

Country Link
JP (1) JPH0680015B2 (en)
AU (1) AU600724B2 (en)
BE (1) BE1001425A4 (en)
CH (1) CH672989A5 (en)
DE (1) DE3715662A1 (en)
DK (1) DK237187A (en)
FR (1) FR2600895B1 (en)
GB (1) GB2194886B (en)
IE (1) IE59895B1 (en)
LU (1) LU86875A1 (en)
NL (1) NL8701113A (en)
NZ (1) NZ220260A (en)
SE (1) SE8701921L (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0780784B2 (en) * 1987-10-23 1995-08-30 宇部興産株式会社 Myocardial ischemic injury therapeutic agent based on microcirculatory disorder
NZ230808A (en) * 1988-10-24 1993-04-28 Squibb & Sons Inc Pharmaceutical compositions and combinations containing an angiotensin-converting enzyme inhibitor and a thrombolytic agent
DE4038563A1 (en) * 1990-12-04 1992-06-11 Gruenenthal Gmbh USE OF SUPEROXIDE DISMUTASES FOR PROPHYLAXIS AND / OR TREATMENT OF ORGAN FAILURE IN RISK PATIENTS WITH POLYTRAUMA
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DE19518625C2 (en) * 1995-05-24 1997-08-07 Buescher Pebueso Beton Process for sealing concrete pipes and a concrete pipe suitable for carrying out the process
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
JP4846799B2 (en) 2005-07-05 2011-12-28 バイオテンプト ベー．フェー． Tumor treatment
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
WO2011013668A1 (en) * 2009-07-27 2011-02-03 国立大学法人新潟大学 Pharmaceutical composition for treatment of ischemic events
US10617756B2 (en) 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8003402A (en) * 1980-06-11 1982-01-04 Leuven Res & Dev Vzw NEW PLASMINOGEN ACTIVATOR AND PHARMACEUTICAL PREPARATION WITH THROMBOLYTIC ACTION.
EP0112122B1 (en) * 1982-12-14 1991-08-28 South African Inventions Development Corporation Plasminogen activator
JPS59196824A (en) * 1983-04-21 1984-11-08 Kowa Co Adsorption inhibitor
SE462893B (en) * 1985-05-28 1990-09-17 Wellcome Found Aqueous PARENTERAL SOLUTION OF TISSUE PLASMINOGEN ACTIVATOR AND SET FOR PREPARATION OF IT
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
WO1987006831A1 (en) * 1986-05-15 1987-11-19 Emory University Composition and method for treating a thrombus and embolus

Also Published As

Publication number Publication date
GB8711058D0 (en) 1987-06-17
SE8701921D0 (en) 1987-05-11
GB2194886A (en) 1988-03-23
DK237187A (en) 1987-11-13
FR2600895B1 (en) 1993-12-24
NL8701113A (en) 1987-12-01
BE1001425A4 (en) 1989-10-31
DE3715662A1 (en) 1987-11-19
IE59895B1 (en) 1994-04-20
SE8701921L (en) 1987-11-13
AU600724B2 (en) 1990-08-23
NZ220260A (en) 1990-07-26
FR2600895A1 (en) 1988-01-08
JPS6322026A (en) 1988-01-29
JPH0680015B2 (en) 1994-10-12
LU86875A1 (en) 1988-01-20
DK237187D0 (en) 1987-05-11
CH672989A5 (en) 1990-01-31
AU7270487A (en) 1987-11-19
GB2194886B (en) 1990-04-25

Similar Documents

Publication Publication Date Title
IE871210L (en) Tissue plasminogen activator
CA2166480A1 (en) Cold sterilant with extended active life
AU6414498A (en) Composition comprising immunoglobulin
AU4135289A (en) Pharmaceutically active combination
GB2207351B (en) Neutral endopeptidase inhibitors as agents for diuresis, natriuresis and thus lowering of blood pressure
CA2088343A1 (en) Stable fibrinogen solution
EP1310256A3 (en) Use of prostaglandin A or its derivatives for the treatment of psoriasis
TW337997B (en) Pharmaceutical preparation containing plasminogen activators
GR3034946T3 (en) Preparation of factor ix.
EP0199117A3 (en) New therapeutical use of phosphocreatine
JPS5587712A (en) Skin cosmetic
EP0208785A4 (en) Fibrinophilic urokinase complex and process for its preparation.
JPS5692217A (en) Easily absorbable enzyme preparation
ES2000033A6 (en) Liquid stable anthelmintic and fungicidal composition based on bithionol sulfoxide.
AU2001288229A1 (en) An advantageous carrier solution for vitrifiable concentrations of cryoprotectants, and compatible cryoprotectant mixtures
IE791183L (en) Phenylpropynylamino benzoic acids
EP0340933A3 (en) Heparin-containing formulations
JPS57142913A (en) Donor of physiologically active substance
AU6997287A (en) The application of tissue plasminogen activator and oxypurinol in dissolving blood clots and in preventing damage to ischaemic tissue during reperfusion
AU1911088A (en) Treatment of cardiac arrhythmias
WO2002008174A8 (en) Phenylethylamine derivatives and their use in the treatment of melanoma
Blasig et al. Effect of activated oxygen species on mitochondria isolated from myocardium after reperfusion injury
IE890270L (en) Proteins derived from human alpha 2 plasmin inhibitor
EP0277751A3 (en) Modified fibrinolytic enzyme
JPS6466130A (en) High polymer carcinostatic enhancer

Legal Events

Date Code Title Description
MM4A Patent lapsed